These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27099274)

  • 1. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis.
    Iannaccone M; D'Ascenzo F; Templin C; Omedè P; Montefusco A; Guagliumi G; Serruys PW; Di Mario C; Kochman J; Quadri G; Biondi-Zoccai G; Lüscher TF; Moretti C; D'amico M; Gaita F; Stone GW
    Eur Heart J Cardiovasc Imaging; 2017 Feb; 18(2):159-166. PubMed ID: 27099274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
    Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference of neointimal growth patterns in bifurcation lesions among four kinds of drug-eluting stents: an optical coherence tomographic study.
    Yoshimura T; Tanaka A; Mori N; Nakamura D; Taniike M; Makino N; Egami Y; Shutta R; Tanouchi J; Nishino M
    Catheter Cardiovasc Interv; 2014 Nov; 84(5):742-9. PubMed ID: 24497273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography.
    Ohtani H; Kimura S; Sugiyama T; Hishikari K; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hikita H; Ashikaga T; Takahashi A; Isobe M
    Int J Cardiovasc Imaging; 2017 Feb; 33(2):177-186. PubMed ID: 27761750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography.
    Chen BX; Ma FY; Luo W; Ruan JH; Xie WL; Zhao XZ; Sun SH; Guo XM; Wang F; Tian T; Chu XW
    Heart; 2008 May; 94(5):566-70. PubMed ID: 17923466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of everolimus-eluting stent incomplete stent apposition: a serial optical coherence tomography analysis.
    Shimamura K; Kubo T; Akasaka T; Kozuma K; Kimura K; Kawamura M; Sumiyoshi T; Ino Y; Yoshiyama M; Sonoda S; Igarashi K; Miyazawa A; Uzui H; Sakanoue Y; Shinke T; Morino Y; Tanabe K; Kadota K; Kimura T
    Eur Heart J Cardiovasc Imaging; 2015 Jan; 16(1):23-8. PubMed ID: 25342855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography.
    Choi HH; Kim JS; Yoon DH; Hong KS; Kim TH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):491-7. PubMed ID: 21442265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT).
    Kim JS; Kim BK; Jang IK; Shin DH; Ko YG; Choi D; Hong MK; Cho YK; Nam CW; Hur SH; Choi JH; Song YB; Hahn JY; Choi SH; Gwon HC; Jang Y
    Am Heart J; 2012 Apr; 163(4):601-7. PubMed ID: 22520526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular imaging analysis of a drug-eluting balloon followed by a bare metal stent compared to a drug-eluting stent for treatment of de novo lesions.
    Choi W; Chae IH; Park JJ; Kim SH; Kang SH; Oh IY; Yoon CH; Cho YS; Youn TJ; Choi DJ
    Korean J Intern Med; 2019 Jul; 34(4):819-829. PubMed ID: 29961306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study.
    Guagliumi G; Sirbu V; Bezerra H; Biondi-Zoccai G; Fiocca L; Musumeci G; Matiashvili A; Lortkipanidze N; Tahara S; Valsecchi O; Costa M
    JACC Cardiovasc Interv; 2010 Jun; 3(6):680-7. PubMed ID: 20630463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial randomized comparison of strut coverage of everolimus- and first-generation sirolimus-eluting stents.
    Kim JS; Kim JH; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Can J Cardiol; 2015 Jun; 31(6):723-30. PubMed ID: 25882337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.
    Sotomi Y; Onuma Y; Dijkstra J; Miyazaki Y; Kozuma K; Tanabe K; Popma JJ; de Winter RJ; Serruys PW; Kimura T
    Eur Heart J Cardiovasc Imaging; 2018 Jan; 19(1):59-66. PubMed ID: 28158421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
    Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study.
    Kim SJ; Lee H; Cho JM; Park CB; Kim W; Kato K; Yonetsu T; Kim CJ; Jang IK
    Coron Artery Dis; 2013 Aug; 24(5):431-9. PubMed ID: 23722649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.